HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania

Dolutegravir Regimen Dried blood spot Cross-sectional study
DOI: 10.1371/journal.pone.0307003 Publication Date: 2024-08-14T17:27:01Z
ABSTRACT
Background Tanzania has made significant progress in improving access to HIV care and treatment. However, virologic suppression among people living with (PLHIV) not been fully realized. In March 2019, introduced a World Health Organization (WHO)—recommended dolutegravir-based regimen as the default first-line regimen. Eighteen months later we investigated viral rates factors associated lack of PLHIV (children adults) Tanzania. Methodology A cross-sectional survey was conducted from September December 2020 on antiretroviral therapy (ART) Whole blood samples, demographic data clinical information were obtained eligible adults (≥15 years) children (< 15 attending thirty-six treatment centres located 22 regions mainland. whole sample each participant processed into plasma load estimated using real-time PCR. defined at cut-off < 50 copies/mL recommended by WHO. Analyses descriptive statistics establish national representative prevalence suppression, logistic regression analyses determine independent non-suppression. Results total 2,039 ART recruited; these, 57.5% (n = 1173) 42.5% 866), respectively. Among adult population, mean age standard deviation (SD) 42.1 ± 12.4 years, 64.7% being female. children, SD 9.6 3 53.2% Overall (undetectable) achieved 87.8% 74.4% children. Adults recorded 89.7% 85.1% Factors independently status population adherence while sex, adherence, current (p<0.05). Conclusion Dolutegravir-based regimens are promising help attain epidemic control More efforts especially needed optimal outcomes for
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (0)